Home » Stocks » Antares Pharma

Antares Pharma, Inc. (ATRS)

Stock Price: $2.61 USD -0.07 (-2.61%)
Updated Jul 31, 2020 4:00 PM EDT - Market closed
Pre-market: $2.70 +0.09 (3.45%) Aug 3, 7:00 AM

Stock Price Chart

Key Info

Market Cap 432.11M
Revenue (ttm) 133.66M
Net Income (ttm) 1.16M
Shares Out 165.56M
EPS (ttm) 0.01
PE Ratio 261.00
Forward PE 34.72
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 31, 2020
Last Price $2.61
Previous Close $2.68
Change ($) -0.07
Change (%) -2.61%
Day's Open 2.66
Day's Range 2.56 - 2.68
Day's Volume 1,204,927
52-Week Range 1.60 - 5.13

More Stats

Market Cap 432.11M
Enterprise Value 428.83M
Earnings Date (est) Aug 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 165.56M
Float 152.86M
EPS (basic) 0.02
EPS (diluted) 0.01
FCF / Share 0.06
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.38%
FCF Yield 2.16%
Payout Ratio n/a
Shares Short 5.34M
Short Ratio 5.57
Short % of Float 3.38%
Beta 1.35
PE Ratio 261.00
Forward PE 34.72
P/FCF Ratio 46.19
PS Ratio 3.23
PB Ratio 8.25
Revenue 133.66M
Operating Income 4.60M
Net Income 1.16M
Free Cash Flow 9.36M
Net Cash 3.29M
Net Cash / Share 0.02
Gross Margin 54.91%
Operating Margin 3.44%
Profit Margin 0.90%
FCF Margin 7.00%
ROA 2.44%
ROE 2.40%
ROIC 5.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$6.25*
(139.46% upside)
Low
4.50
Current: $2.61
High
8.00
Target: 6.25
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue12463.5554.5252.2245.6626.5020.6222.5816.4612.82
Revenue Growth94.9%16.58%4.39%14.38%72.28%28.53%-8.67%37.17%28.39%-
Gross Profit73.3932.4927.0523.4126.2015.2611.4213.069.668.55
Operating Income0.99-4.10-15.59-24.12-20.46-35.11-20.85-11.45-4.44-6.03
Net Income-2.03-6.52-16.74-24.34-20.66-35.15-20.51-11.43-4.39-6.09
Shares Outstanding16315715615514713112711096.9983.17
Earnings Per Share-0.01-0.04-0.11-0.16-0.14-0.27-0.16-0.10-0.05-0.07
Operating Cash Flow-10.62-17.32-23.09-15.20-28.20-26.33-14.97-10.47-1.93-6.08
Capital Expenditures2.656.650.73-4.88-5.64-4.66-2.74-3.26-0.32-0.06
Free Cash Flow-7.97-10.68-22.36-20.08-33.84-31.00-17.71-13.73-2.25-6.14
Cash & Equivalents45.7227.8931.5627.7247.9140.0363.0873.2131.379.85
Total Debt47.0925.1324.86-------
Net Cash / Debt-1.362.776.7027.7247.9140.0363.0873.2131.379.85
Assets13388.2874.3466.3384.5668.7788.9395.5341.9615.14
Liabilities78.2549.2840.7921.1117.5227.5818.228.9810.828.51
Book Value54.5039.0033.5545.2267.0441.2070.7186.5531.146.63
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Antares Pharma, Inc.
Country United States
Employees 178
CEO Robert F. Apple

Stock Information

Ticker Symbol ATRS
Stock Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Unique Identifier NASDAQ: ATRS
IPO Date October 2, 1996

Description

Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., Idorsia Pharmaceuticals Ltd, and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.